FocalTherics (FOCL) to Release Earnings on Thursday

FocalTherics (NASDAQ:FOCL) is expected to announce its Q2 2026 results before the market opens on Thursday, August 27th. Analysts expect FocalTherics to announce earnings of ($0.2287) per share and revenue of $22.4840 million for the quarter. Interested persons can find conference call details on the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

FocalTherics (NASDAQ:FOCL) last issued its earnings results on Friday, August 14th. The company reported ($0.39) EPS for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.19). The company had revenue of $13.20 million during the quarter. FocalTherics had a negative return on equity of 248.00% and a negative net margin of 56.26%. On average, analysts expect FocalTherics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

FocalTherics Stock Performance

Shares of NASDAQ:FOCL opened at $4.18 on Tuesday. The stock has a market capitalization of $156.88 million, a price-to-earnings ratio of -4.06 and a beta of -0.04. The stock’s 50 day moving average is $5.34. FocalTherics has a one year low of $1.30 and a one year high of $6.40. The company has a current ratio of 1.60, a quick ratio of 1.38 and a debt-to-equity ratio of 1.79.

Insider Activity

In related news, Director David R. Horn bought 10,000 shares of the stock in a transaction on Friday, August 14th. The stock was bought at an average price of $4.75 per share, for a total transaction of $47,500.00. Following the completion of the acquisition, the director directly owned 10,000 shares in the company, valued at approximately $47,500. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, CEO Ryan Rhodes bought 21,000 shares of the company’s stock in a transaction on Friday, August 14th. The shares were bought at an average cost of $4.75 per share, for a total transaction of $99,750.00. Following the transaction, the chief executive officer directly owned 626,649 shares in the company, valued at approximately $2,976,582.75. This represents a 3.47% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. In the last quarter, insiders purchased 116,000 shares of company stock valued at $551,000. 10.10% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in FocalTherics stock. Rock Springs Capital Management LP boosted its stake in shares of FocalTherics (NASDAQ:FOCL) by 1.3% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,286,500 shares of the company’s stock after purchasing an additional 16,500 shares during the quarter. Rock Springs Capital Management LP owned about 3.44% of FocalTherics worth $4,233,000 as of its most recent filing with the Securities and Exchange Commission (SEC). Hedge funds and other institutional investors own 62.74% of the company’s stock.

Wall Street Analyst Weigh In

Several brokerages recently issued reports on FOCL. Piper Sandler reissued a “neutral” rating and issued a $4.00 price objective on shares of FocalTherics in a research note on Friday, August 14th. Wall Street Zen lowered FocalTherics from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Mizuho set a $15.00 target price on FocalTherics and gave the stock an “outperform” rating in a report on Friday, July 17th. Weiss Ratings reissued a “sell (d-)” rating on shares of FocalTherics in a research report on Monday, August 17th. Finally, HC Wainwright reissued a “buy” rating and set a $10.00 price target on shares of FocalTherics in a research report on Tuesday, June 2nd. One research analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, two have assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, FocalTherics has a consensus rating of “Hold” and a consensus target price of $7.75.

About FocalTherics

EDAP TMS SA, together with its subsidiaries, develops, produces, markets, distributes, and maintains a portfolio of minimally invasive medical devices for the treatment of urological diseases in Asia, France, the United States, and internationally. It operates in three segments: High Intensity Focused Ultrasound (HIFU), Extracorporeal ShockWave Lithotripsy (ESWL), and Distribution Services (DIST). The HIFU segment develops, manufactures, and markets medical devices based on HIFU technology for the minimally invasive treatment of urological and other clinical indications.